Catherine Stehman-Breen, Chroma Medicine CEO
March 1, 2023 06:00 AM ESTUpdated 06:38 AM
Financing
Bioregnum
Cell/Gene Tx

A gene edit­ing 3.0 play­er goes deep on cash, fron­tier sci­ence to put pre­ci­sion epi­ge­net­ics to the big test

Is­si Rozen is as deeply em­bed­ded in­to the gene edit­ing field as any­one in the buzzy Cam­bridge, MA biotech hub. As chief busi­ness of­fi­cer and …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Trump asks 'very tough hom­bre' Dr. Oz to lead MFN talks

US warns drug­mak­ers against mis­rep­re­sent­ing cost of im­port­ed prod­ucts

About 5% of CBER and CDER left af­ter FDA staff cuts, analy­sis finds

Meet the ‘first sale’ rule: A cus­toms loop­hole phar­ma com­pa­nies could use to ease tar­iff im­pact

End­points 100 biotech sur­vey: Wel­come to the sum­mer of biotech’s dis­con­tent

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times